These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 1296011)
41. The mild hypertension dilemma: results of the British MRC trial. Miall WE J Clin Hypertens; 1986 Sep; 2(3 Suppl):12S-21S. PubMed ID: 3098929 [No Abstract] [Full Text] [Related]
42. The Mayo three-community hypertension control program. V. Cost-effectiveness of intervention. Christianson JB; Krishan I; Nobrega FT; Davis CS; Smoldt RK; Harris AM Mayo Clin Proc; 1981 Jan; 56(1):11-6. PubMed ID: 6779059 [TBL] [Abstract][Full Text] [Related]
43. [Influential factors of treatment cost of antihypertensive drugs for hypertensive patient in community]. Feng R; Wang Z; Cui Y; Wang X; Wang X Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 40(3):291-7. PubMed ID: 25832531 [TBL] [Abstract][Full Text] [Related]
47. Definition of the dilemma of the scope of diagnostic investigation in the community hypertension program. Blaufox MD Bull N Y Acad Med; 1976; 52(6):671-9. PubMed ID: 823990 [No Abstract] [Full Text] [Related]
48. [Cost benefit analysis in the health services]. Luković G Lijec Vjesn; 1975 Mar; 97(3):164-6. PubMed ID: 808675 [No Abstract] [Full Text] [Related]
52. Coronary disease in the community. Goble AJ Aust Nurses J; 1971 Jul; 1(1):26-8. PubMed ID: 5211155 [No Abstract] [Full Text] [Related]
53. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies]. Rorive G; Delporte JP Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395 [TBL] [Abstract][Full Text] [Related]
54. Moderately elevated blood pressure. A report from SBU, the Swedish Council on Technology Assessment in Health Care. J Intern Med Suppl; 1995; 737():1-225. PubMed ID: 9043531 [No Abstract] [Full Text] [Related]
55. Hypertension, a health economics perspective. Alcocer L; Cueto L Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):147-55. PubMed ID: 19124418 [TBL] [Abstract][Full Text] [Related]
56. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension]. Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623 [No Abstract] [Full Text] [Related]
57. Community attributable risk: its economic dimensions. Wilhelmsen L J Hum Hypertens; 1992 Dec; 6(6):469-72. PubMed ID: 1296011 [No Abstract] [Full Text] [Related]
58. Costs and benefits of community programmes for the control of hypertension. Nissinen A; Tuomilehto J; Enlund H; Kottke TE J Hum Hypertens; 1992 Dec; 6(6):473-9. PubMed ID: 1296012 [No Abstract] [Full Text] [Related]